Surbhi Leekha1, Lyndsay M O'Hara1, Alyssa Sbarra2, Shanshan Li3, Anthony D Harris1. 1. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. 2. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut. 3. Mass Mutual Financial Group, New York, New York.
Abstract
OBJECTIVE: To evaluate whether clinical cultures are an appropriate surrogate for surveillance cultures to measure the effect of interventions on the incidence of MRSA and VRE in the hospital. DESIGN: Cross-sectional and quasi-experimental, retrospective analysis. SETTING AND POPULATION: Convenience sample of patients admitted between January 1, 2002, and June 31, 2011, to the medical intensive care unit (MICU) and surgical intensive care unit (SICU) of an acute-care hospital in the United States. INTERVENTIONS: Asynchronously in the MICU and SICU, we introduced (1) universal glove and gown use, (2) bundled intervention to prevent central-line-associated bloodstream infection, and (3) daily chlorhexidine gluconate bathing. RESULTS: We observed a statistically significant correlation between surveillance and clinical culture-based incidence rates of MRSA in the MICU (0.32; P < .001) and the SICU (0.37; P < .001) but not for VRE in either the MICU (0.16, P = .11) or the SICU (0.15; P = .12). For VRE, but not for MRSA, incidence density rates based on surveillance cultures were 2- to 4-fold higher than for clinical cultures. When evaluating the impacts of the interventions, different effect estimates were noted for universal glove and gown use on MRSA acquisition in MICU, and for VRE acquisition in both the MICU and the SICU based on surveillance versus clinical cultures. CONCLUSIONS: For multidrug-resistant organism acquisition, surveillance cultures should be used when feasible because clinical cultures may not be an appropriate surrogate. Clinical or surveillance-based end points for infection control interventions should reflect the conceptual model from colonization to infection and where an intervention might have an effect, rather than considering them interchangeable.
OBJECTIVE: To evaluate whether clinical cultures are an appropriate surrogate for surveillance cultures to measure the effect of interventions on the incidence of MRSA and VRE in the hospital. DESIGN: Cross-sectional and quasi-experimental, retrospective analysis. SETTING AND POPULATION: Convenience sample of patients admitted between January 1, 2002, and June 31, 2011, to the medical intensive care unit (MICU) and surgical intensive care unit (SICU) of an acute-care hospital in the United States. INTERVENTIONS: Asynchronously in the MICU and SICU, we introduced (1) universal glove and gown use, (2) bundled intervention to prevent central-line-associated bloodstream infection, and (3) daily chlorhexidine gluconate bathing. RESULTS: We observed a statistically significant correlation between surveillance and clinical culture-based incidence rates of MRSA in the MICU (0.32; P < .001) and the SICU (0.37; P < .001) but not for VRE in either the MICU (0.16, P = .11) or the SICU (0.15; P = .12). For VRE, but not for MRSA, incidence density rates based on surveillance cultures were 2- to 4-fold higher than for clinical cultures. When evaluating the impacts of the interventions, different effect estimates were noted for universal glove and gown use on MRSA acquisition in MICU, and for VRE acquisition in both the MICU and the SICU based on surveillance versus clinical cultures. CONCLUSIONS: For multidrug-resistant organism acquisition, surveillance cultures should be used when feasible because clinical cultures may not be an appropriate surrogate. Clinical or surveillance-based end points for infection control interventions should reflect the conceptual model from colonization to infection and where an intervention might have an effect, rather than considering them interchangeable.
Authors: Alexandre R Marra; Michael B Edmond; Marin L Schweizer; Grace W Ryan; Daniel J Diekema Journal: Am J Infect Control Date: 2017-10-12 Impact factor: 2.918
Authors: Susan S Huang; Deborah S Yokoe; Virginia L Hinrichsen; Laura S Spurchise; Rupak Datta; Irina Miroshnik; Richard Platt Journal: Clin Infect Dis Date: 2006-09-14 Impact factor: 9.079
Authors: Michael W Climo; Deborah S Yokoe; David K Warren; Trish M Perl; Maureen Bolon; Loreen A Herwaldt; Robert A Weinstein; Kent A Sepkowitz; John A Jernigan; Kakotan Sanogo; Edward S Wong Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: Anthony D Harris; Lisa Pineles; Beverly Belton; J Kristie Johnson; Michelle Shardell; Mark Loeb; Robin Newhouse; Louise Dembry; Barbara Braun; Eli N Perencevich; Kendall K Hall; Daniel J Morgan; Syed K Shahryar; Connie S Price; Joseph J Gadbaw; Marci Drees; Daniel H Kett; L Silvia Muñoz-Price; Jesse T Jacob; Loreen A Herwaldt; Carol A Sulis; Deborah S Yokoe; Lisa Maragakis; Matthew E Lissauer; Marcus J Zervos; David K Warren; Robin L Carver; Deverick J Anderson; David P Calfee; Jason E Bowling; Nasia Safdar Journal: JAMA Date: 2013-10-16 Impact factor: 56.272
Authors: David P Calfee; Eve T Giannetta; Lisa J Durbin; Teresa P Germanson; Barry M Farr Journal: Clin Infect Dis Date: 2003-07-14 Impact factor: 9.079